{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010956","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.368212+00:00","generated_at":"2026-06-17T09:26:41.979169+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio reports FY2022 net loss $28.5M; cash $18.2M; clinical data positive","bullets":["Cash $18.2M at Dec 31, 2022, down from $37.0M a year earlier; R&D spend $14.1M (FY2022) vs $7.3M.","Net loss $28.5M ($1.36/share) for FY2022 vs $14.7M ($1.47/share) in FY2021; Q4 loss $7.8M ($0.32/share).","INB-100 leukemia patients maintain durable complete responses beyond 18 months, up to 2.7 years in Phase 1.","INB-200 GBM trial: two patients progression-free at 1.5 and 1.2 years; enrolling Cohort 3; updated data mid-2023.","FDA cleared IND for INB-400 Phase 2 trial in GBM; enrollment expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010956","json":"https://secwatch.observer/filing/0000950170-23-010956.json","markdown":"https://secwatch.observer/filing/0000950170-23-010956.md","text":"https://secwatch.observer/filing/0000950170-23-010956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/0000950170-23-010956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/inab-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:26:41.979169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"358ea30df604c604447df407c5fbcd2983561bc8","claim":"IN8BIO, INC. reported financial results for the fourth quarter and full-year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/0000950170-23-010956-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}